Latest News

Apply now for Vaccine Development Services



TRANSVAC 2 Open Call for Vaccine Development Services

Developing a vaccine is a time-consuming and complex process, requiring a combination of specialised skills and technical capacities not readily available at a single organisation. To facilitate access to these skills and capacities, TRANSVAC2 offers high-quality technical services to support the development of prophylactic and therapeutic vaccines for both human and animal use. These services, which include Instruct-ERIC structural biology services, are not restricted to any disease area. Services will be offered free of charge, with few exceptions. Academic and non-academic research groups, SMEs and industries can apply.


Structural Biology Services for Vaccine Development

To access structural biology infrastructure for vaccine research, you can apply directly through Instruct-ERIC at any time. Simply choose the technology that you require and then submit a research proposal. Funding is available to researchers working in Instruct Member Countries and Organisations.


In-person and remote access routes available at Instruct Centres

Given the current travel restrictions, many of Instruct-ERIC’s facilities are offering remote access to their services. To find out more, view Instruct’s Technology Availability List.


Multidisciplinary vaccine projects

If you would like to use other vaccine services in addition to structural biology, you can still apply to use Instruct’s infrastructure via TRANSVAC2. Successful applications from researchers in Instruct Member Countries and Organisations will be funded by Instruct-ERIC.


How to Apply

To apply for structural biology services directly from Instruct-ERIC you can submit a proposal at any time.

To apply for the TRANSVAC2 Vaccine Development Services, which includes Instruct-ERIC structural biology services, submit your application by 15 December 2020 at



TRANSVAC2 is a European vaccine research and development (R&D) infrastructure project dedicated to accelerating the development of safe, effective and affordable vaccines. TRANSVAC2 has received funding from the European Union's Horizon 2020 research and innovation program under grant agreement N° 730964.